The Scottish Medicines Consortium (SMC) has accepted AstraZeneca and MSD’s Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone for adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated, regardless of biomarker status1. Prostate cancer is the most common cancer among Scottish males, affecting […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!